Follow-on investment in Lunaphore
OCCIDENT participated in this Series D1 totaling 40 million Swiss francs under the lead of Ernst-Göhner Stiftung Beteiligungen (EGSB).
News
Follow-up Investment in Resistell
OCCIDENT has been invested in Resistell since the seed financing and is now again participating in the first tranche of 8.5 million of the Series B.
Initial investment in core sensing
OCCIDENT invests in an innovative sensor technology for machine components and takes the lead for the Series A of 4.5M growth capital at core sensing.
Initial investment in Avelo
OCCIDENT further strengthens its portfolio in the field of diagnostics and leads Avelo’s oversubscribed 2.2 million seed financing round.
Successful Exit Versantis
French buyer GENFIT, a late-stage biopharmaceutical company, aims to strengthen its position as a leader in acute-on-chronic liver failure (ACLF).
adivo achieves two major milestones
Our portfolio company adivo, focusing on developing the next generation of species-specific targeted drugs for companion animals, has announced the achievements of two major milestones.
mk2 announces joint development project
mk2 Biotechnologies, WACKER and the Technical University of Munich (TUM) today announced their joint project for various applications.
Follow-up investment in Code Intelligence
After the team has consistently impressed us over the past years and the company has developed very positively, OCCIDENT is once again investing in the Bonn-based startup Code Intelligence.
Follow-up investment in Tubulis
OCCIDENT participated in this € 60 million Series B led by Andera Partners with participation from new investors Evotec and Fund+.